Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares, rose in value, with the stock price down by -1.82% to the previous day’s close as strong demand from buyers drove the stock to $10.78.
Actively observing the price movement in the last trading, the stock closed the session at $10.98. The value of beta (5-year monthly) was 0.83. Referring to stock’s 52-week performance, its high was $16.75, and the low was $4.54. On the whole, RXRX has fluctuated by 10.06% over the past month.
With the market capitalization of Recursion Pharmaceuticals Inc currently standing at about $2.33 billion, investors are eagerly awaiting this quarter’s results, scheduled for May 06, 2024 – May 10, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.43, which is expected to increase to -$0.38 for fiscal year -$1.73 and then to about -$1.89 by fiscal year 2025. Data indicates that the EPS growth is expected to be -9.50% in 2025, while the next year’s EPS growth is forecast to be -9.20%.
Analysts have estimated the company’s revenue for the quarter at $13.07 million, with a low estimate of $10 million and a high estimate of $20.8 million. According to the average forecast, sales growth in current quarter could jump up 7.70%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $57.3 million, representing an increase of 28.50% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that RXRX’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium term indicators have put the stock in the category of 50% Buy while long term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of RXRX currently trading nearly -13.44% and -4.08% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 45.42, while the 7-day volatility ratio is showing 10.84% which for the 30-day chart, stands at 10.56%. Furthermore, Recursion Pharmaceuticals Inc (RXRX)’s beta value is 0.81, and its average true range (ATR) is 1.17.
A comparison of Recursion Pharmaceuticals Inc (RXRX) with its peers suggests the former has fared considerably weaker in the market. RXRX showed an intraday change of -1.82% in last session, and over the past year, it grew by 41.28%%.
Data on historical trading for Recursion Pharmaceuticals Inc (NASDAQ:RXRX) indicates that the trading volumes over the past 10 days have averaged 6.72 million and over the past 3 months, they’ve averaged 6.88 million. According to company’s latest data on outstanding shares, there are 226.26 million shares outstanding.
Nearly 32.10% of Recursion Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 77.28% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 42.82 million shares as on Feb 29, 2024, resulting in a short ratio of 5.5. According to the data, the short interest in Recursion Pharmaceuticals Inc (RXRX) stood at 18.25% of shares outstanding as of Feb 29, 2024; the number of short shares registered in Jan 31, 2024 reached 38.27 million. The stock has risen by 9.33% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the RXRX stock heading into the next quarter.
